A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)
Latest Information Update: 26 Feb 2026
At a glance
- Drugs Ianalumab (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Acronyms VAY2EXPLORE
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 26 Feb 2026 New trial record